US Stock MarketDetailed Quotes
IXHL Incannex Healthcare
- 1.980
- +0.010+0.52%
Close Nov 22 16:00 ET
- 1.750
- -0.230-11.63%
Post 19:25 ET
34.94MMarket Cap-1456P/E (TTM)
2.030High1.960Low12.40KVolume1.960Open1.970Pre Close24.80KTurnover0.09%Turnover RatioLossP/E (Static)17.64MShares12.68052wk High5.29P/B26.58MFloat Cap1.50052wk Low--Dividend TTM13.42MShs Float360.000Historical High--Div YieldTTM3.55%Amplitude1.500Historical Low1.999Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Incannex Healthcare Stock Forum
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors
Incannex Healthcare Inc - FDA Approves Phase 2 Clinical Trial for Incannex
Dosing Completed in 115 Participant Bioavailability/Bioequivalence
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
Incannex Healthcare Inc. (Nasdaq: IXHL), biotechnology company, specializing in cannabinoid and psychedelic medicine, marked a significant milestone on May 7, 2024, with the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA). This crucial step forward perta...
Incannex Complete Successful Pre-Ind Meeting With the FDA for Cannquit-O for Treatment of Opioid Use Disorder
No comment yet